Advertisement
Advertisement

AVXL

AVXL logo

Anavex Life Sciences

2.86
USD
Sponsored
+0.01
+0.35%
Sep 04, 15:59 UTC -4
Closed
exchange

After-Market

2.90

+0.04
+1.43%

Anavex Life Sciences Profile

About

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.

Info & Links

CEO

Christopher Missling

Headquarters

630 5TH AVENUE, 20TH FLOOR
NEW YORK, NY 10111, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.anavex.com

Auditor

GRANT THORNTON LLP

Share holders

49

Employees

34

Anavex Life Sciences Statistics

Valuation Measures

Market Capitalization2

268.91M

Enterprise Value

137.16M

Enterprise Value/EBITDA(ttm)

-3.08

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

2.38

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-11.43%

Return on Invested Capital(ttm)

-12.27%

Return on Assets(ttm)

-10.72%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-44.60M

Net Income Available to Common(ttm)

-39.95M

Diluted EPS(ttm)

-0.15

Share Statistics

Beta (5Y Monthly)

1.14

52-Week Change

-69.93%

S&P 500 52-Week Change

19.68%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

92.67M

Dividend Yield

0.00%

Float4

82.13M

% Held by Insiders

11.40%

% Held by Institutions

31.55%

Balance Sheet

Total Cash(mrq)

131.75M

Total Cash Per Share(mrq)

1.42

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

15.62%

Quick Ratio(mrq)

20.87%

Book Value Per Share(mrq)

1.21

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.22

Free Cash Flow(ytd)

-20.69M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement